Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 126Lung Neoplasms 51Triple Negative Breast Neoplasms 35Breast Neoplasms 34Small Cell Lung Carcinoma 30Ovarian Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Neoplasm Metastasis 21Fallopian Tube Neoplasms 20Endometrial Neoplasms 19Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 14Head and Neck Neoplasms 13Colorectal Neoplasms 11Carcinoma 11Prostatic Neoplasms 9Oropharyngeal Neoplasms 9Esophageal Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 7Lung Diseases 6Laryngeal Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma of Lung 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Mouth Neoplasms 5Mesothelioma 5

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Carboplatin × 90 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡